Cite
HARVARD Citation
Lesniewski-Kmak, K. et al. (n.d.). O-022Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis. Annals of oncology. p. . [Online].